BR9809120A - Uso de 5-(4-(2-(n-metil-n-(2-piridil)amino)-etóxi)benzil)2,4-tiazo lidinodiona no tratamento de sìndrome policìstica do ovário e diabetes decorrente de gestação - Google Patents

Uso de 5-(4-(2-(n-metil-n-(2-piridil)amino)-etóxi)benzil)2,4-tiazo lidinodiona no tratamento de sìndrome policìstica do ovário e diabetes decorrente de gestação

Info

Publication number
BR9809120A
BR9809120A BR9809120-4A BR9809120A BR9809120A BR 9809120 A BR9809120 A BR 9809120A BR 9809120 A BR9809120 A BR 9809120A BR 9809120 A BR9809120 A BR 9809120A
Authority
BR
Brazil
Prior art keywords
pregnancy
amino
methyl
treatment
polycystic ovary
Prior art date
Application number
BR9809120-4A
Other languages
English (en)
Inventor
Tammy Antonucci
Dean Lockwood
Rebecca Norris
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9809120A publication Critical patent/BR9809120A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção:<B>"USO DE 5-(4-(2-(N-METIL-N-(2-PIRIDIL)AMINO)-E-TóXI)BENZIL)2,4-TIAZO LIDINODIONA NO TRATAMENTO DE SìNDROME POLICìSTICA DO OVáRIO E DIABETES DECORRENTE DE GESTAçãO"<D>. Esta invenção apresenta novos métodos de uso de derivados de tiazolidinona e agentes anti-hiperglicêmicos afins para tratar populações em risco de desenvolver diabetes melito não-dependente de insulina (NIDDM) e complicações que se originam dele. Em uma modalidade, os compostos da invenção são usados para tratar síndrome policística do ovário a fim de prevenir ou retardar o início de diabetes melito não-dependente de insulina. Em outra modalidade, os compostos da invenção são usados para tratar diabetes decorrente de gestação a fim de prevenir ou retardar o início de diabetes melito-não-dependente de insulina.
BR9809120-4A 1997-05-15 1998-05-14 Uso de 5-(4-(2-(n-metil-n-(2-piridil)amino)-etóxi)benzil)2,4-tiazo lidinodiona no tratamento de sìndrome policìstica do ovário e diabetes decorrente de gestação BR9809120A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/856,987 US5874454A (en) 1993-09-15 1997-05-15 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
PCT/US1998/010113 WO1998051305A1 (en) 1997-05-15 1998-05-14 Use of 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)-ethoxy)benzyl)2,4-thiazolidinedione in the treatment of polycystic ovary syndrome and gestational diabetes

Publications (1)

Publication Number Publication Date
BR9809120A true BR9809120A (pt) 2000-08-01

Family

ID=25324901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9809120-4A BR9809120A (pt) 1997-05-15 1998-05-14 Uso de 5-(4-(2-(n-metil-n-(2-piridil)amino)-etóxi)benzil)2,4-tiazo lidinodiona no tratamento de sìndrome policìstica do ovário e diabetes decorrente de gestação

Country Status (14)

Country Link
US (1) US5874454A (pt)
EP (1) EP0981346A1 (pt)
JP (1) JP2001525827A (pt)
KR (1) KR20010012556A (pt)
AU (1) AU731690B2 (pt)
BR (1) BR9809120A (pt)
CA (1) CA2282473A1 (pt)
HU (1) HUP0003397A3 (pt)
IL (1) IL132125A0 (pt)
IS (1) IS5177A (pt)
NO (1) NO995549D0 (pt)
PL (1) PL336764A1 (pt)
WO (1) WO1998051305A1 (pt)
ZA (1) ZA984084B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
GB0019223D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
LT3412302T (lt) 2014-10-24 2021-07-26 Bristol-Myers Squibb Company Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
RU2665969C1 (ru) * 2017-05-04 2018-09-05 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ лечения синдрома поликистозных яичников

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4873255A (en) * 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
DE3856378T2 (de) * 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
US5223522A (en) * 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5120754A (en) * 1988-03-08 1992-06-09 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5061717A (en) * 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US4897405A (en) * 1989-04-21 1990-01-30 American Home Products Corporation Novel naphthalenylalkyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents
GB8919434D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
JP3544659B2 (ja) * 1990-02-09 2004-07-21 ファルマシア・アンド・アップジョン・カンパニー インスリン感性化剤類の高血圧治療のための使用
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
ES2092112T3 (es) * 1991-06-25 1996-11-16 Pfizer Agentes hipoglicemicos de tiazolidindiona.
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ATE376829T1 (de) * 1993-09-15 2007-11-15 Daiichi Sankyo Co Ltd Verwendung von thiazolidindionen zur vorbeugung oder verzögerung des auftretens des nichtinsulinabhängigen diabetes mellitus (niddm)

Also Published As

Publication number Publication date
IL132125A0 (en) 2001-03-19
JP2001525827A (ja) 2001-12-11
ZA984084B (en) 1998-11-20
AU731690B2 (en) 2001-04-05
KR20010012556A (ko) 2001-02-15
NO995549L (no) 1999-11-12
WO1998051305A1 (en) 1998-11-19
NO995549D0 (no) 1999-11-12
PL336764A1 (en) 2000-07-17
CA2282473A1 (en) 1998-11-19
HUP0003397A2 (hu) 2002-01-28
EP0981346A1 (en) 2000-03-01
AU7494998A (en) 1998-12-08
US5874454A (en) 1999-02-23
IS5177A (is) 1999-09-10
HUP0003397A3 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
BR9809968A (pt) Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional
WO1995007697A3 (en) Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
BR9809120A (pt) Uso de 5-(4-(2-(n-metil-n-(2-piridil)amino)-etóxi)benzil)2,4-tiazo lidinodiona no tratamento de sìndrome policìstica do ovário e diabetes decorrente de gestação
BR0014003A (pt) Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra
CO4940465A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol-3- il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
YU7998A (sh) Heterociklična jedinjenja i njihove farmaceutske kompozicije
WO2002038544A3 (en) 3-substituted oxindole beta 3 agonists
CY1105254T1 (el) Θepαπεια του διαβητη με θειαζολιδινδιονη, εκκριταγωγο ινσουλινης και διγουανιδιο
DE59913784D1 (de) Verwendung von Thiazolidinderivaten als antihyperglykämische Mittel
RS51343B (sr) Nova kompozicija i njena upotreba
BR9815747A (pt) Composição para liberação de aroma
ATE268750T1 (de) Proteintyrosinphosphatase inhibitoren
BR0113473A (pt) Dispersão aquosa e seu uso na preparação de materiais de revestimento, adesivos e compostos de selagem actìnicos e curáveis com calor.
NO2009002I1 (no) 5-{4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl}tiazolidin-2,4-dionmaleat(salter/solvater)+glimepirid
ATE169225T1 (de) Anwendung von urodilatin bei lungen- und bronchialerkrankungen
SE9702680D0 (sv) New formulation
MA26511A1 (fr) Compositions pharmaceutiques comprenant de la 5-(4-(2-(n-methyl-n-(2-pyridyl) amino) ethoxy) benzyl)-thiazolidine-2,4-dione et de l&#39;insuline pour une methode de traitement.
BR0311834A (pt) Composto, composição farmacêutica, métodos para mudular um receptor ativado por proliferador de peroxisoma, para tratar e prevenir diabetes mellitus em um mamìfero e para tratar sìndrome x em um mamìfero, e, uso de um composto ou seu sal farmaceuticamente aceitável
DK0902658T3 (da) Anordning til transport af et knoglesegment til overdækning af en knogledefekt
DK0764022T3 (da) Agonister og antagonister af de nikotinerge acetylcholinreceptorer hos insekter som endoparasiticider
ATE252913T1 (de) Vorbeugung einer krankheit mit diabetes charakter
AP9901696A0 (en) Composition comprising 5-(4-(2-(N-methyl-N-2-pyridyl)amino) ehtoxy benzyl)thiazolidine-2,4-dione
NO20001937D0 (no) 2-substituerte 1,2-benzisotiazol-derivater og deres anvendelse som serotonin-antagonister (5-HT1A, 5-HT1B og 5-HT1D)
DE60122580D1 (de) 5-4&#39;-2&#39;-(n-methyl-n-(2-pyridyl)amino) ethoxy!benzyl!thiazolidin-2,4-dion mesylatsalz

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.